BRAF and melanoma: Indeed, it has been shown that in patients with advanced BRAF mutated melanoma undergoing treatment with TT, higher levels of plasma circulating tumour DNA (ctDNA) may predict disease progression earlier than imaging and/or clinical assessments [39].